FDA Prioritizes Priority
Executive Summary
FDA's Office of New Drugs issues policy to expedite an NDA, BLA or efficacy supplement classification. The revised review classification policy now directs divisions to identify whether an application may qualify for a priority designation within 14 days of an application's receipt. If a priority designation is expected, the filing meeting to determine the review classification and first-cycle review timeline should occur by day 30 instead of day 45, the standard review date, a July 16 1Manual of Policies and Procedures states...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.